Phase I/Ib trial of bavituximab in combination with durvalumab in patients with multiple solid tumors

Trial Profile

Phase I/Ib trial of bavituximab in combination with durvalumab in patients with multiple solid tumors

Suspended
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Bavituximab (Primary) ; Durvalumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Mar 2016 According to a Peregrine Pharmaceuticals media release, status changed from planning to suspended.
    • 09 Mar 2016 According to a Peregrine Pharmaceuticals media release, due to setback development in the SUNRISE trial, the companies (Peregrine and AstraZeneca) are currently working together to identify the optimal path forward for demonstrating potential mechanistic synergies between bavituximab and durvalumab in different patient populations. The expected timing of initiation of this trial will be determined upon finalization of its trial design.
    • 10 Dec 2015 According to a company media release, Peregrine Pharmaceuticals expects to initiate this study in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top